|
|
Correction, Vol. 8, No. 7
In the article, “Monitoring Antimicrobial Use and Resistance: Comparison
with a National Benchmark on Reducing Vancomycin Use and Vancomycin-Resistant
Enterococci” by Scott K. Fridkin et al., errors occurred in the table
on page 705. The corrected table appears below and online at http://www.cdc.gov/ncidod/eid/vol8no7/01-0465.htm.
We regret any confusion these errors may have caused.
| Table. Prescribing
practice changes implemented in response to benchmark data intervention,
and mean rate of vancomycin usea before and after intervention,
50 Project ICARE ICUs, January 1996–July 1999b |
|
| Vancomycin
use prescribing practice change |
No. of ICUs (%)
(n=50)
|
Vancomycin use before and after
practice change
|
p valuec
|
|
|
Change absent
|
Change present
|
|
|
|
Before
|
After
|
Before
|
After
|
|
|
Hospitalwided
|
22 (44)
|
|
|
|
|
|
|
Drug use evaluation
|
19 (38)
|
74.2
|
80.5
|
105.3
|
94.1
|
0.62
|
|
Redistributed HICPAC guidelines on VRE
|
9 (18)
|
79.4
|
84.6
|
116.0
|
90.6
|
0.34
|
|
Prior approval of vancomycin required
|
3 (6)
|
87.2
|
84.7
|
67.2
|
99.4
|
0.25
|
|
Unit-specificd
|
11 (22)
|
|
|
|
|
|
|
ICU-specific education on appropriate vancomycin
use
|
9 (18)
|
75.9
|
83.3
|
132.1
|
96.3
|
0.01
|
|
Removed vancomycin from surgical prophylaxis
|
3 (6)
|
82.0
|
85.9
|
149.1
|
82.2
|
0.01
|
|
|
aDefined daily doses per 1,000 patient-days.
bICARE, Intensive Care Antimicrobial
Resistance Epidemiology; ICU, intensive-care units; HICPAC, Healthcare
Infection Control Practices Advisory Committee; VRE, vancomycin-resistant
enterococci.
cPaired t-test.
dComponents of each major category
are not mutually exclusive, so one ICU may be represented in several
components of each category.
|
|
